| P50 | author | Siegfried Kasper | Q2283474 |
| | Rolf R. Engel | Q46789021 |
| P2093 | author name string | A Horvath | |
| | R Grohmann | |
| | K Papageorgiou | |
| | A Konstantinidis | |
| P2860 | cites work | Second-generation antipsychotics in major depressive disorder: update and clinical perspective | Q37810765 |
| | National patterns in antidepressant medication treatment | Q38449365 |
| | A novel augmentation strategy for treating resistant major depression | Q43514882 |
| | Use of antipsychotics in the treatment of major depressive disorder in the U.S. Department of Veterans Affairs | Q45331501 |
| | Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. | Q46027622 |
| | Outcome in delusional depression comparing trimipramine monotherapy with a combination of amitriptyline and haloperidol--a double-blind multicenter trial | Q46225467 |
| | Tardive Dyskinesia: analysis of outpatients with schizophrenia from Africa and the Middle East, Asia, Central and Eastern Europe, and Latin America | Q46240177 |
| | Risperidone for treatment-refractory major depressive disorder: a randomized trial | Q46920652 |
| | Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. | Q48765516 |
| | Conventional Antipsychotic Prescription in Unipolar Depression, I | Q56595089 |
| | Quetiapine in combination with citalopram in patients with unipolar psychotic depression | Q57738570 |
| | How much do novel antipsychotics benefit the patients? | Q57739326 |
| | Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study | Q79440232 |
| | Antidepressant drug effects and depression severity: a patient-level meta-analysis | Q24598580 |
| | Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies | Q28247669 |
| | Neurological complications of psychiatric drugs: clinical features and management | Q28262051 |
| | A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder | Q28291261 |
| | Tolerability of atypical antipsychotics | Q33876248 |
| | The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. | Q34004814 |
| | Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies. | Q34018482 |
| | National trends in psychotropic medication polypharmacy in office-based psychiatry | Q34090959 |
| | World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care | Q34578945 |
| | Therapeutic options for treatment-resistant depression | Q34615947 |
| | Which antidepressants have demonstrated superior efficacy? A review of the evidence | Q34698836 |
| | Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials | Q34997918 |
| | Patterns of atypical antipsychotic subtherapeutic dosing among Oregon Medicaid patients | Q35163507 |
| | The AMSP drug safety program: methods and global results | Q35723762 |
| | Changes in antipsychotic drug prescribing by general practitioners in the United Kingdom from 1991 to 2000: a population-based observational study | Q35825831 |
| | Therapy of treatment resistant depression: focus on the management of TRD with atypical antipsychotics | Q35936252 |
| | Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder | Q37055322 |
| | Augmentation of antidepressants with atypical antipsychotics: a review of the current literature | Q37062820 |
| | The under-recognized role of dopamine in the treatment of major depressive disorder | Q37095070 |
| | Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. | Q37281749 |
| | Polypharmacy prevalence rates in the treatment of unipolar depression in an outpatient clinic | Q37356659 |
| P433 | issue | 4 | |
| P304 | page(s) | 449-457 | |
| P577 | publication date | 2011-05-17 | |
| P1433 | published in | The International Journal of Neuropsychopharmacology | Q7742309 |
| P1476 | title | Increase of antipsychotic medication in depressive inpatients from 2000 to 2007: results from the AMSP International Pharmacovigilance Program | |
| P478 | volume | 15 | |